Cerenome, Inc. - Asset Resilience Ratio
Cerenome, Inc. (CNSY) has an Asset Resilience Ratio of 44.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CNSY total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Cerenome, Inc.'s Asset Resilience Ratio has changed over time. See Cerenome, Inc. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Cerenome, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cerenome, Inc. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.22 Million | 44.34% |
| Total Liquid Assets | $6.22 Million | 44.34% |
Asset Resilience Insights
- Very High Liquidity: Cerenome, Inc. maintains exceptional liquid asset reserves at 44.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cerenome, Inc. Industry Peers by Asset Resilience Ratio
Compare Cerenome, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 0.77% |
Annual Asset Resilience Ratio for Cerenome, Inc. (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Cerenome, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $4.36 Million | $16.32 Million | -26.54pp |
| 2024-12-31 | 53.22% | $3.53 Million | $6.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $11.39 Million | -- |
| 2006-12-31 | 15.99% | $3.98 Million | $24.87 Million | -11.84pp |
| 2005-12-31 | 27.83% | $7.84 Million | $28.17 Million | -13.71pp |
| 2004-12-31 | 41.54% | $10.58 Million | $25.47 Million | +0.78pp |
| 2003-12-31 | 40.76% | $11.45 Million | $28.09 Million | -9.79pp |
| 2002-12-31 | 50.55% | $19.88 Million | $39.32 Million | -21.89pp |
| 2001-12-31 | 72.44% | $31.25 Million | $43.14 Million | +1.63pp |
| 2000-12-31 | 70.80% | $37.01 Million | $52.27 Million | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more